ArticleMycoses2021
Trichosporon asahii superinfections in critically ill COVID-19 patients overexposed to antimicrobials and corticosteroids.
Article in Mycoses, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 21 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
21 citing papers in PubMed, 36 citations in OpenAlex.
- Article
- In Silico Analysis and Expression Profiling of Adhesin-Like Flocculins in Trichosporon asahii.Mycopathologia · 2026Article
- Detection of Multiple Nosocomial Trichosporon asahii Transmission Events via Microsatellite Typing Assay, South America.Emerging infectious diseases · 2025Article
- Biocide Tolerance, Biofilm Formation, and Efflux Pump Activity in Clinical Isolates ofInfectious disease reports · 2025Article
- Article
- Article
- Transcriptomics Uncovers Key Genes for Photodynamic Killing on Trichosporon asahii Biofilms.Mycopathologia · 2025Article
- Rare Yeasts in Latin America: Uncommon Yet Meaningful.Journal of fungi (Basel, Switzerland) · 2023Review
- Article
- Clinical Challenges of Emerging and Re-Emerging Yeast Infections in the Context of the COVID-19 Pandemic.Microorganisms · 2022Review
- Fungal Bloodstream Co-infection by Trichosporon asahii in a COVID-19 Critical Patient: Case Report and Literature Review.Mycopathologia · 2022Review
- An overview of COVID-19 related to fungal infections: what do we know after the first year of pandemic?Brazilian journal of microbiology : [publication of the Brazilian Society for Microbiology] · 2022Review
- Fungal Infections in Critically Ill COVID-19 Patients: Inevitabile Malum.Journal of clinical medicine · 2022Review
- COVID-19-associated brain abscess caused byMedical mycology case reports · 2022Article
- The Continuing Emergence ofJournal of fungi (Basel, Switzerland) · 2022Article
- Diagnosis of invasive fungal disease in coronavirus disease 2019: approaches and pitfalls.Current opinion in infectious diseases · 2021Review
- Trichosporon asahii superinfections in critically ill COVID-19 patients overexposed to antimicrobials and corticosteroids.Mycoses · 2021Article
- Risk Factors for Fungal Co-Infections in Critically Ill COVID-19 Patients, with a Focus on Immunosuppressants.Journal of fungi (Basel, Switzerland) · 2021Review
- Article
- Trichosporon asahii fungemia and COVID-19 co-infection: An emerging fungal pathogen; case report and review of the literature.IDCases · 2021Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors at 2 institutions in 1 country.
Funding
Abstract
objectivesTo investigate the occurrence of Trichosporon asahii fungemia among critically ill COVID-19 patients.
methodsFrom 1 July to 30 September 2020, cases of T asahii fungemia (TAF) in a Brazilian COVID-19 referral centre were investigated. The epidemiology and clinical courses were detailed, along with a mycological investigation that included molecular species identification, haplotype diversity analysis and antifungal susceptibility testing.
resultsFive critically ill COVID-19 patients developed TAF in the period. All five patients had common risk conditions for TAF: central venous catheter at fungemia, previous exposure to broad-spectrum antibiotics, prior echinocandin therapy and previous prolonged corticosteroid therapy. The average time of intensive care unit hospitalisation previous to the TAF episode was 23 days. All but one patient had voriconazole therapy, and TAF 30-day mortality was 80%. The five T asahii strains from the COVID-19 patients belonged to 4 different haplotypes, mitigating the possibility of skin origin and cross-transmission linking the 5 reported episodes. The antifungal susceptibility testing revealed low minimal inhibitory concentrations for azole derivatives.
conclusionsJudicious prescription of antibiotics, corticosteroids and antifungals needs to be discussed in critically ill COVID-19 patients to prevent infections by hard-to-treat fungi like T asahii.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.